Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

Related news

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

ANABAnaptysBio, Inc.2026-06-25 13:46 EST

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

View all latest news

AnaptysBio, Inc.

AnaptysBio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANABAnaptysBio, Inc.2026-06-26 02:34 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ANABAnaptysBio, Inc.2026-06-26 02:34 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

ANABAnaptysBio, Inc.2026-06-26 02:34 EST

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANABAnaptysBio, Inc.2026-06-26 02:34 EST

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary

ANABAnaptysBio, Inc.2026-06-26 02:34 EST

Anaptys Announces Participation at Upcoming Investor Conferences

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States